Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Relapsed and refractory multiple myeloma (RRMM) presents significant treatment challenges, especially after failure of standard therapies.
• B-cell maturation antigen (BCMA) is a key target for novel myeloma therapies.
• Bispecific antibodies offer a promising approach to redirect T-cell immunity against cancer cells.

Purpose of the Study:

• To review and critically appraise the evidence for elranatamab, a BCMA x CD3 bispecific antibody, in RRMM.
• To evaluate its mechanism of action, clinical efficacy, safety, and patient-reported outcomes.
• To position elranatamab within the current landscape of BCMA-directed therapies.

Main Methods:

• Systematic review and critical appraisal of published clinical studies and real-world data on elranatamab.
• Analysis of efficacy endpoints including response rates and duration of response.
• Assessment of safety profiles, including cytokine release syndrome and neurotoxicity, with a focus on step-up dosing strategies.

Main Results:

• Elranatamab demonstrated high overall response rates and durable disease control in heavily pretreated RRMM patients.
• The safety profile was manageable, characterized by predominantly low-grade cytokine release syndrome and limited neurotoxicity with step-up dosing.
• Efficacy appears preserved in patients previously treated with BCMA-targeted therapies and feasible in high-risk populations.

Conclusions:

• Elranatamab is a valuable addition to the therapeutic options for RRMM, offering significant clinical activity.
• Further research is needed to optimize sequencing, understand long-term benefits, manage infection risks, and explore combination strategies.
• Real-world data and ongoing trials will be crucial for defining elranatamab's precise role in RRMM treatment.